Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
Gainers
Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.
This Biotechnology Stock Is Trading Lower By 77%, Here Are 62 Stocks Moving In Monday’s Mid-Day Session
Gainers
Ontrak, Inc. (NASDAQ: OTRK) gained 102% to $1.3150. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022.
Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket
Gainers
MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00 per share.
This Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday
Gainers
Getty Images Holdings, Inc. (NYSE: GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with special-purpose acquisition company (SPAC) CC Neuberger Principal Holdings (CCNB).
Short Volatility Alert: BiomX Inc.
On Thursday, shares of BiomX Inc. (NYSE: PHGE) experienced volatile short activity. After the activity, the stock price went up +18.89% to $1.07.
The overall sentiment for PHGE has been Bearish.
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer’s Drug Due In January, FDA Reviews Roche’s Lymphoma Candidate, Rare Pediatric Tag For Kazia’s Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Agile Therapeutics, Inc. (NASDAQ: AGRX) jumped 88.9% to $2.3986. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.
Boehringer Ingelheim And BiomX Collaborate To Discover Inflammatory Bowel Disease Microbiome Biomarkers
BiomX's XMarker biomarker discovery platform to potentially inform Boehringer Ingelheim's development of IBD therapeutics
Marks the second agreement between Boehringer Ingelheim and BiomX focused on IBD
BiomX
BiomX Announces Dosing Of The First Two Patients In Phase 1b/2a Study Of BX004 For Treatment Of Chronic Respiratory Infections In Patients With Cystic Fibrosis
BiomX Inc. (NYSE:PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today